



Published in final edited form as:

ACS Chem Biol. 2016 January 15; 11(1): 25–30. doi:10.1021/acscchembio.5b00439.

## Wall teichoic acids prevent antibody binding to epitopes within the cell wall of *Staphylococcus aureus*

Samir Gautam<sup>†,§</sup>, Taehan Kim<sup>§</sup>, Evan Lester<sup>§</sup>, Deeksha Deep<sup>§</sup>, and David A. Spiegel<sup>\*,§,‡</sup>

<sup>†</sup>Department of Cell Biology, Yale School of Medicine, 333 Cedar Street, New Haven, Connecticut 06520, United States


<sup>‡</sup>Department of Pharmacology, Yale School of Medicine, 333 Cedar Street, New Haven, Connecticut 06520, United States

<sup>§</sup>Department of Chemistry, Yale University, 225 Prospect Street, New Haven, Connecticut 06511, United States

### Abstract

*Staphylococcus aureus* is a Gram-positive bacterial pathogen that produces a range of infections including cellulitis, pneumonia, and septicemia. The principle mechanism in antistaphylococcal host defense is opsonization with antibodies and complement proteins, followed by phagocytic clearance. Here we use a previously developed technique for installing chemical epitopes in the peptidoglycan cell wall to show that surface glycopolymers known as wall teichoic acids conceal cell wall epitopes, preventing their recognition and opsonization by antibodies. Thus, our results reveal a previously unrecognized immunoevasive role for wall teichoic acids in *S. aureus*: repulsion of peptidoglycan-targeted antibodies

### Graphical abstract



*Staphylococcus aureus* is a Gram-positive pathogen that claims nearly 20 000 lives in the United States each year through serious infections such as pneumonia and septicemia and imposes a major financial burden through common infections such as cellulitis.<sup>1</sup> Host defense against *S. aureus* primarily depends on phagocytic clearance by macrophages and neutrophils recruited to sites of infection. These innate immune cells identify and phagocytose *S. aureus* via opsonins that coat the bacterial cell surface— principally,

\*Corresponding Author: david.spiegel.@yale.edu.

#### Notes

The authors declare the following competing financial interest(s): D.A.S. is a paid consultant for Bristol-Myers Squibb.

#### Supporting Information

The Supporting Information is available free of charge on the ACS Publications website at DOI: 10.1021/acscchembio.5b00439. Supporting figures and experimental methods (PDF) Three-dimensional SIM imaging (AVI)

antibodies and complement.<sup>2</sup> Following internalization, bacteria are killed through multiple mechanisms, including oxidative damage, enzymatic degradation, and antimicrobial peptide-induced lysis.<sup>2</sup> *S. aureus* has evolved a myriad of immunoevasion mechanisms targeting each of these steps: i.e., phagocyte recruitment, immune detection, and intraphagosomal killing.<sup>3</sup>

Wall teichoic acids (WTA) are glycopolymers covalently attached to the peptidoglycan (PG) cell wall in Gram-positive bacteria. Extending beyond the cell wall, they form a dense, highly charged glycan layer at the cell surface,<sup>4,5</sup> where they play key roles in *S. aureus* physiology, regulating ion homeostasis<sup>6</sup>, autolysis<sup>7-10</sup>, and PG biosynthesis<sup>11,12</sup>. WTAs also contribute to the pathogenesis of *S. aureus* infection by mediating adherence to host tissues.<sup>13-16</sup> In addition, the WTA layer serves as a physical barrier to shield *S. aureus* from a broad array of environmental threats, ranging from antimicrobial surfactants to bacteriolytic enzymes (e.g., lysozyme).<sup>17,18</sup>

In keeping with this protective role, we hypothesized that WTAs may also function as an “immunological cloak” for *S. aureus*, preventing antibodies from recognizing and opsonizing the cell wall. PG represents an ideal target for the immune system because its structure is highly conserved across bacterial species and absent in mammalian tissue.<sup>19</sup> Indeed, antibodies targeting the cell wall could conceivably provide broad protection against *S. aureus* (and possibly other Gram-positive species as well), given the conservation of PG structure and the fact that Gram-positive bacteria lack an outer membrane to protect PG from immune recognition. Thus, concealing cell wall epitopes with WTAs would be a highly advantageous immunoevasive strategy.

To explore the hypothesis that WTAs block antibody binding to *S. aureus* PG, we first needed to identify a cell wall-specific antigen to which we could test recruitment of a cognate antibody. Unfortunately, commercially available antistaphylococcal PG antibodies are raised against whole cell immunogens (not purified<sup>20</sup> or chemically synthesized<sup>21</sup> PG antigens) and may therefore recognize non-PG epitopes. To circumvent this problem, we reasoned that we could install an exogenous chemical antigen in the cell wall and assess recruitment of a highly specific antibody to this foreign epitope.

To execute this strategy, we made use of a “chemical surface display”<sup>22</sup> technique previously developed in our lab, which enables insertion of nonnative chemical moieties into the cell wall of *S. aureus* via sortase A.<sup>23</sup> Sortase A is an enzyme that resides on the extracellular face of the plasma membrane, where it recognizes the pentapeptide motif LPxTG in secreted proteins (wherein x can be any amino acid). The enzyme cleaves between the threonine and glycine of this motif and then attaches the LPxT peptide along with its N-terminal protein cargo to the PG bridge peptide (Figure S1a,b).<sup>24</sup> Through the same mechanism, incubating bacteria with synthetic LPxTG peptides carrying N-terminal chemical cargo leads to covalent “biosynthetic” incorporation of exogenous compounds into the cell wall of *S. aureus* (Figure S1c).<sup>23</sup> As shown previously, this labeling process takes place under standard laboratory growth conditions and has no appreciable effects on cell viability or morphology.<sup>23</sup>

Utilizing this technique, we sought to install the chemical epitope fluorescein isothiocyanate (FITC) into the cell wall of *S. aureus* using the probe K(FITC)-LPETG (Figure S1c). We then sought to assess recruitment of antibodies to PG-bound FITC in the presence and absence of WTAs in order to test the role of these glycopolymers in immunoevasion. Following the protocol of Campbell et al.,<sup>12</sup> we depleted WTA by treating cells with 0.1  $\mu\text{g mL}^{-1}$  tunicamycin, a concentration that selectively inhibits the first gene in the WTA biosynthetic pathway, TagO, without altering cell viability.<sup>12</sup>

To control for nonspecific sticking of the probe to the cell surface, which could lead to deposition of FITC epitopes on non-PG envelope structures (and thus “off-target” antibody recruiting), we labeled parallel sets of samples with the isomeric scrambled peptide K(FITC)-EGTLP. As demonstrated previously, this control peptide recapitulates the nonspecific binding properties of the LPETG probe but is not incorporated into PG by sortase A.<sup>23</sup> Therefore, comparisons between EGTLP- and LPETG-treated samples allow for specific quantification of antibody recruitment to PG-bound epitopes.

As an additional control, we performed our experiments in the *spa S. aureus* Newman mutant. This strain lacks expression of protein A, a surface protein that binds to the Fc portion of many mammalian antibody isotypes.<sup>25</sup> Hence, the use of *spa S. aureus* eliminates protein A-mediated antibody binding, allowing specific detection of antibody recruitment to FITC. To test whether *spa S. aureus* is capable of incorporating K(FITC)-LPETG, both in the presence and absence of WTA, we labeled mutant bacteria with and without tunicamycin. As shown in Figure S2a, flow cytometry measurements of cellular FITC fluorescence demonstrated effective labeling with K(FITC)-LPETG under both conditions.

Having confirmed that the *spa* mutant efficiently incorporates FITC into the cell wall, we assessed antibody recruitment to PG-bound FITC by incubating cells with DyLight 649-conjugated anti-FITC antibodies, and then measuring cellular FL-4 fluorescence via flow cytometry. Strikingly, we observed no antibody binding at all in native bacteria, but after inhibition of WTA synthesis with tunicamycin, we observed substantial recruitment (Figure 1a).

The small increase in binding in the tunicamycin-treated EGTLP sample compared with the untreated EGTLP control most likely represents antibody recognition of probe that is nonspecifically adsorbed to the WTA-denuded cell wall. Indeed, flow cytometry quantification of EGTLP probe labeling demonstrated that the peptide bound much more avidly to cells in the absence of WTA (Figure S2b). This finding may be explained by the relative hydrophobicity of the exposed PG cell wall in TCM-treated cells compared to the highly charged WTA layer present in native bacteria—a property that likely promotes nonspecific sticking of peptide probes. However, as stated above, the substantial increase in antibody recruiting in the tunicamycin-treated LPETG sample compared to the corresponding EGTLP control demonstrates specific recognition of epitopes covalently linked to PG.

Next, to confirm that antibody binding to cell wall epitopes is a result of WTA removal *per se* and not an artifact of tunicamycin treatment, we tested recruitment in *tagO S. aureus* Newman, which is genetically deficient in WTA synthesis (Figure 1b). In this strain, we did observe substantial binding of antibody to DMSO-treated cells (likely attributable to protein A-mediated capture) and to nonspecifically adsorbed EGTLP probe. However, there was also a significant increase in antibody recruitment to PG-bound FITC in *tagO S. aureus* (Figure 1b) that was not observed in WTA-expressing cells (Figure 1a). This result further supports the essential role of WTAs in blocking antibody binding to cell wall epitopes.

We then leveraged a unique property of anti-FITC antibodies—their ability to quench the fluorescence of FITC upon binding—to demonstrate a direct physical interaction between antibody and PG-bound epitope. To this end, we labeled *spa S. aureus* with K(FITC)-LPETG in the presence and absence of tunicamycin and then incubated cells with various concentrations of anti-FITC antibodies. As shown in Figure 1c, there was a progressive decrease in FITC fluorescence with increasing concentrations of anti-FITC antibody in WTA-depleted *S. aureus*. This result indicates fluorescence quenching due to direct antibody binding to fluorophore. No such quenching was observed with an anti-DNP control, demonstrating specific antibody recognition of FITC. Quenching was also absent in WTA-expressing cells, again confirming WTA's critical role in impeding antibody recruitment. Of note, the modest degree of quenching we observed (~10% at the highest antibody concentration) is likely attributable to the relative impermeability of the cell wall to antibodies. Binding is probably restricted to superficial PG-linked FITC molecules, whereas the majority of epitopes are likely buried within the PG meshwork, inaccessible to antibodies.

Imaging studies were then performed to further demonstrate that antibodies are able to recognize cell wall epitopes only in the absence of wall teichoic acids. First, we imaged recruitment of antibodies to FITC, and consistent with our flow cytometry results (Figure 1a), we found that antibodies only bound to cells that had been labeled with K(FITC)-LPETG and depleted of WTAs (Figure 1d).

Next, to directly visualize the relationship between epitope and antibody, we incorporated the more photostable fluorophore Alexa 488 into the cell wall via K(A488)-LPETG and recruited anti-A488 antibodies. As shown in Figure 2a (left panels), the A488 epitope was distributed uniformly throughout the cell wall, including the septum (see inset). Antibodies, meanwhile, only bound to the exterior portion of the cell wall, without penetrating into the septum. Super-resolution images further showed that antibody predominantly coated the surface of the cell wall (Figure 2b, Movie S1), a result that is fully consistent with the quenching data (Figure 1c), which suggested that only superficial PG-bound epitopes are available for binding.

Finally, we sought to demonstrate that WTAs serve as a barrier against binding of not only antibodies but proteins in general. To this end, we tested whether the 53-kDa protein streptavidin could be recruited to PG-bound biotin in the presence and absence of WTAs in WT *S. aureus* (note: the use of the *spa* mutant in this experiment was unnecessary, as streptavidin does not bind to protein A). Indeed, consistent with the antibody recruiting

results presented in Figure 1a, streptavidin only bound its target when WTA synthesis was inhibited (Figure 3).

In this study, we have employed a unique “chemical surface display”<sup>22</sup> strategy to interrogate the role of WTA at the interface between *S. aureus* and the immune system. Using sortase-targeted peptides, we were able to biosynthetically incorporate several chemical epitopes (FITC, Alexa 488, and biotin) at a precisely defined site in the peptidoglycan sacculus under the WTA layer. Then, using specific recognition proteins for these epitopes, we generated multiple lines of evidence to show that WTAs serve as a barrier against opsonin recruitment to the cell wall (Figure 4). This barrier function most likely derives from the density and charge of WTAs, which in turn lead to steric and/or electrostatic repulsion of opsonins.

According to this model, cell wall-associated proteins (CWAPs, Figure S1) must extend beyond the WTA layer since they are recognized by antibodies in native *S. aureus*.<sup>26</sup> This exposure is likely necessary for the particular functions of CWAPs (e.g., protein A intercepting host antibodies, clumping factor B mediating adhesion to host tissue, etc.<sup>27</sup>), but it also leaves them susceptible to antibody-mediated immunity. It may be that *S. aureus* is able to tolerate such immune responses because CWAPs are often functionally redundant and therefore poorly conserved.<sup>27</sup> Indeed, vaccine studies have shown that broad protection against *S. aureus* cannot be achieved through an antibody response to any single CWAP; multiple antigens must be targeted simultaneously.<sup>28</sup>

In contrast, the basic structure of PG is nearly invariable between *S. aureus* strains. In fact, PG structure is so well-conserved that it represents a bacterial pathogen-associated molecular pattern (PAMP)—a molecular signature for the presence of invading bacteria—that is recognized by a dedicated set of innate immune receptors: NOD1 and NOD2.<sup>19</sup> Thus, it would appear critical to conceal this highly conserved antigen from antibodies, which may otherwise provide broad, species-wide protection against *S. aureus*—and perhaps other Gram-positive bacteria as well.

It is interesting to note that antibodies against staphylococcal PG are virtually ubiquitous in human sera.<sup>29,30</sup> The reason for their inefficacy against *S. aureus* is unclear, but it may be that they are simply obstructed from binding their targets by WTA. Indeed, the effectiveness of pharmacological WTA inhibitors and diminished virulence of WTA-depleted *S. aureus* in animal infection models may be attributable in part to the exposure of PG to such antibodies.<sup>13,15,16,31,32</sup> Further studies will be needed to test this hypothesis.

WTA itself also serves as a target for the human immune system, as it is recognized by both antibodies and the soluble pattern recognition molecule, mannose binding lectin.<sup>33,34</sup> Similarly to anti-PG immunity, humoral responses against WTA fail to provide adequate antistaphylococcal defense. However, murine vaccine studies have shown that boosting anti-WTA antibody titers can provide protection, suggesting that the inefficacy of WTA antibodies may be attributable to insufficient quantity rather than antigenic inaccessibility.<sup>35</sup>

The notion that WTA functions as a cloak for PG to prevent detection by the immune system fits well with several previous studies. Recently, Fura et al. reported an immunotherapeutic

strategy against *S. aureus* in which dinitrophenol (DNP) modified D-amino acids are incorporated into peptidoglycan and used to recruit anti-DNP antibodies present in human serum.<sup>36</sup> Consistent with our findings, they showed that antibody recruiting to PG-bound DNP greatly improved in the absence of WTA. Similarly, An et al. have demonstrated that human serum amyloid protein (SAP), a component of the acute phase response to infection, is able to recognize PG only in the absence of WTAs.<sup>37</sup> Finally, in *Drosophila*, Atilano et al. have shown that WTAs prevent binding of the innate effector protein, peptidoglycan recognition protein (PGRP), to the staphylococcal cell wall.<sup>38</sup> The same group recently built upon these findings, demonstrating that PGRP recognition of PG could be restored through deletion of the major autolysin, *atl*. They proposed that PG fibers projecting radially from the *S. aureus* cell wall (also observed in immunoelectron microscopy studies<sup>20</sup>) are able to extend beyond the WTA layer where they are susceptible to immune detection unless actively “trimmed” by *atl*.<sup>39</sup> It should be noted, however, that WTA deletion *per se* disrupts *atl* localization<sup>8</sup> and that deletion of WTA and *atl* have additive effects on PGRP recruitment;<sup>39</sup> therefore the role of *atl* in PG exposure is likely multifactorial.

Overall, these findings are in close accordance with the model presented here and point to a conserved role for WTAs in preventing immune recognition of PG in both vertebrate and invertebrate hosts. The discovery of this phenomenon significantly deepens our understanding of the function of WTAs in *S. aureus*, adding them to the already impressive arsenal of immunoevasion mechanisms possessed by this important human pathogen.

These results also raise a number of follow-up questions deserving of further study. One informative direction would be to determine the specific structural components of WTA that mediate the polymer’s antibody-retardant properties. The highly charged ribitol-phosphate backbone of WTA likely plays a role, but its D-alanine and  $\alpha$ - and  $\beta$ -O-N-acetyl-D-glucosamine (GlcNac) substituents may contribute significantly as well. Investigation into such questions should provide important insight into WTA’s emerging role in *S. aureus* pathogenesis and may also reveal novel pharmacologic targets for antistaphylococcal therapy. We believe that the rapidly expanding toolkit of synthetic cell wall probes, including those used here, will serve as a valuable adjunct to more traditional immunology and bacteriology techniques in these endeavors.<sup>23, 40, 41</sup>

## EXPERIMENTAL SECTION

A full description of materials and methods may be found in the Supporting Information

## Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

## Acknowledgments

### Funding

This work was supported by a Camille and Henry Dreyfus Foundation New Faculty Award (to D.A.S.), a Novartis Early Career Award in Organic Chemistry (to D.A.S.), an Alfred P. Sloan Foundation Fellowship (BR2011-117 to D.A.S.), a National Institutes of Health New Innovator Award (1DP2OD002913-01 to D.A.S.), and a National Institutes of Health MSTP training grant (T32GM07205 to S.G.).

We gratefully acknowledge M.G. Pinho and D. Bartel's helpful suggestions during the preparation of this manuscript.

## ABBREVIATIONS

<b>FITC</b>	fluorescein isothiocyanate
<b>PG</b>	peptidoglycan
<b>WTA</b>	wall teichoic acids


## References

1. Viner RM, Coffey C, Mathers C, Bloem P, Costello A, Santelli J, Patton GC. 50-year mortality trends in children and young people: a study of 50 low-income, middle-income, and high-income countries. *Lancet*. 2011; 377:1162–1174. [PubMed: 21450338]
2. DeLeo FR, Diep BA, Otto M. Host defense and pathogenesis in *Staphylococcus aureus* infections. *Infectious disease clinics of North America*. 2009; 23:17–34. [PubMed: 19135914]
3. Kim HK, Thammavongsa V, Schneewind O, Missiakas D. Recurrent infections and immune evasion strategies of *Staphylococcus aureus*. *Curr Opin Microbiol*. 2012; 15:92–99. [PubMed: 22088393]
4. Weidenmaier C, Peschel A. Teichoic acids and related cell-wall glycopolymers in Gram-positive physiology and host interactions. *Nat Rev Microbiol*. 2008; 6:276–287. [PubMed: 18327271]
5. Umeda A, Ueki Y, Amako K. Structure of the *Staphylococcus aureus* cell wall determined by the freeze-substitution method. *J Bacteriol*. 1987; 169:2482–2487. [PubMed: 3584061]
6. Brown S, Santa Maria JP Jr, Walker S. Wall teichoic acids of gram-positive bacteria. *Annu Rev Microbiol*. 2013; 67:313–336. [PubMed: 24024634]
7. Qamar A, Golemi-Kotra D. Dual roles of FmtA in *Staphylococcus aureus* cell wall biosynthesis and autolysis. *Antimicrob Agents Chemother*. 2012; 56:3797–3805. [PubMed: 22564846]
8. Schlag M, Biswas R, Krismer B, Kohler T, Zoll S, Yu W, Schwarz H, Peschel A, Gotz F. Role of staphylococcal wall teichoic acid in targeting the major autolysin Atl. *Mol Microbiol*. 2010; 75:864–873. [PubMed: 20105277]
9. Frankel MB, Schneewind O. Determinants of murein hydrolase targeting to cross-wall of *Staphylococcus aureus* peptidoglycan. *J Biol Chem*. 2012; 287:10460–10471. [PubMed: 22303016]
10. Biswas R, Martinez RE, Gohring N, Schlag M, Josten M, Xia G, Hegler F, Gekeler C, Gleske AK, Gotz F, Sahl HG, Kappler A, Peschel A. Proton-binding capacity of *Staphylococcus aureus* wall teichoic acid and its role in controlling autolysin activity. *PLoS One*. 2012; 7:e41415. [PubMed: 22911791]
11. Atilano ML, Pereira PM, Yates J, Reed P, Veiga H, Pinho MG, Filipe SR. Teichoic acids are temporal and spatial regulators of peptidoglycan cross-linking in *Staphylococcus aureus*. *Proc Natl Acad Sci U S A*. 2010; 107:18991–18996. [PubMed: 20944066]
12. Campbell J, Singh AK, Santa Maria JP Jr, Kim Y, Brown S, Swoboda JG, Mylonakis E, Wilkinson BJ, Walker S. Synthetic lethal compound combinations reveal a fundamental connection between wall teichoic acid and peptidoglycan biosyntheses in *Staphylococcus aureus*. *ACS Chem Biol*. 2011; 6:106–116. [PubMed: 20961110]
13. Weidenmaier C, Kokai-Kun JF, Kristian SA, Chanturiya T, Kalbacher H, Gross M, Nicholson G, Neumeister B, Mond JJ, Peschel A. Role of teichoic acids in *Staphylococcus aureus* nasal colonization, a major risk factor in nosocomial infections. *Nat Med*. 2004; 10:243–245. [PubMed: 14758355]
14. Weidenmaier C, Kokai-Kun JF, Kulauzovic E, Kohler T, Thumm G, Stoll H, Gotz F, Peschel A. Differential roles of sortase-anchored surface proteins and wall teichoic acid in *Staphylococcus aureus* nasal colonization. *Int J Med Microbiol*. 2008; 298:505–513. [PubMed: 18221914]
15. Weidenmaier C, Peschel A, Xiong YQ, Kristian SA, Dietz K, Yeaman MR, Bayer AS. Lack of wall teichoic acids in *Staphylococcus aureus* leads to reduced interactions with endothelial cells and to


- attenuated virulence in a rabbit model of endocarditis. *J Infect Dis.* 2005; 191:1771–1777. [PubMed: 15838806]
16. Weidenmaier C, Peschel A, Kempf VA, Lucindo N, Yeaman MR, Bayer AS. DltABC- and MprF-mediated cell envelope modifications of *Staphylococcus aureus* confer resistance to platelet microbicidal proteins and contribute to virulence in a rabbit endocarditis model. *Infect Immun.* 2005; 73:8033–8038. [PubMed: 16299297]
  17. Bera A, Biswas R, Herbert S, Kulauzovic E, Weidenmaier C, Peschel A, Gotz F. Influence of wall teichoic acid on lysozyme resistance in *Staphylococcus aureus*. *J Bacteriol.* 2007; 189:280–283. [PubMed: 17085565]
  18. Kohler T, Weidenmaier C, Peschel A. Wall teichoic acid protects *Staphylococcus aureus* against antimicrobial fatty acids from human skin. *J Bacteriol.* 2009; 191:4482–4484. [PubMed: 19429623]
  19. Iwasaki A, Medzhitov R. Control of adaptive immunity by the innate immune system. *Nat Immunol.* 2015; 16:343–353. [PubMed: 25789684]
  20. Umeda A, Yokoyama S, Arizono T, Amako K. Location of peptidoglycan and teichoic acid on the cell wall surface of *Staphylococcus aureus* as determined by immunoelectron microscopy. *J Electron Microscopy.* 1992; 41:46–52.
  21. Sandhu S, Schouten JA, Thompson J, Davis M, Bugg TD. Detection of *Staphylococcus aureus* cell walls by enzymelinked immunoassay using antibodies prepared from a semi-synthetic peptidoglycan precursor. *Analyst.* 2012; 137:1130–1136. [PubMed: 22249441]
  22. Gautam S, Gniadek TJ, Kim T, Spiegel DA. Exterior design: strategies for redecorating the bacterial surface with small molecules. *Trends Biotechnol.* 2013; 31:258–267. [PubMed: 23490213]
  23. Nelson JW, Chamessian AG, McEnaney PJ, Murelli RP, Kazmierczak BI, Spiegel DA. A biosynthetic strategy for re-engineering the *Staphylococcus aureus* cell wall with non-native small molecules. *ACS Chem Biol.* 2010; 5:1147–1155. [PubMed: 20923200]
  24. Marraffini LA, Dedent AC, Schneewind O. Sortases and the art of anchoring proteins to the envelopes of gram-positive bacteria. *Microbiol Mol Biol Rev.* 2006; 70:192–221. [PubMed: 16524923]
  25. Lindmark R, Thoren-Tolling K, Sjoquist J. Binding of immunoglobulins to protein A and immunoglobulin levels in mammalian sera. *J Immunol Methods.* 1983; 62:1–13. [PubMed: 6348168]
  26. Hall AE, Domanski PJ, Patel PR, Vernachio JH, Syribeys PJ, Gorovits EL, Johnson MA, Ross JM, Hutchins JT, Patti JM. Characterization of a protective monoclonal antibody recognizing *Staphylococcus aureus* MSCRAMM protein clumping factor A. *Infect Immun.* 2003; 71:6864–6870. [PubMed: 14638774]
  27. Foster TJ, Geoghegan JA, Ganesh VK, Hook M. Adhesion, invasion and evasion: the many functions of the surface proteins of *Staphylococcus aureus*. *Nat Rev Microbiol.* 2014; 12:49–62. [PubMed: 24336184]
  28. Stranger-Jones YK, Bae T, Schneewind O. Vaccine assembly from surface proteins of *Staphylococcus aureus*. *Proc Natl Acad Sci U S A.* 2006; 103:16942–16947. [PubMed: 17075065]
  29. Verbrugh HA, Peters R, Rozenberg-Arska M, Peterson PK, Verhoef J. Antibodies to cell wall peptidoglycan of *Staphylococcus aureus* in patients with serious staphylococcal infections. *J Infect Dis.* 1981; 144:1–9. [PubMed: 7264368]
  30. Sun D, Raisley B, Langer M, Iyer JK, Vedham V, Ballard JL, James JA, Metcalf J, Coggeshall KM. Antipeptidoglycan antibodies and Fcγ receptors are the key mediators of inflammation in Gram-positive sepsis. *J Immunol.* 2012; 189:2423–2431. [PubMed: 22815288]
  31. Wang H, Gill CJ, Lee SH, Mann P, Zuck P, Meredith TC, Murgolo N, She X, Kales S, Liang L, Liu J, Wu J, Santa Maria J, Su J, Pan J, Hailey J, McGuinness D, Tan CM, Flattery A, Walker S, Black T, Roemer T. Discovery of wall teichoic acid inhibitors as potential anti-MRSA beta-lactam combination agents. *Chem Biol.* 2013; 20:272–284. [PubMed: 23438756]
  32. Kristian SA, Lauth X, Nizet V, Goetz F, Neumeister B, Peschel A, Landmann R. Alanylation of teichoic acids protects *Staphylococcus aureus* against Toll-like receptor 2-dependent host defense in a mouse tissue cage infection model. *J Infect Dis.* 2003; 188:414–423. [PubMed: 12870123]



33. Jung DJ, An JH, Kurokawa K, Jung YC, Kim MJ, Aoyagi Y, Matsushita M, Takahashi S, Lee HS, Takahashi K, Lee BL. Specific serum Ig recognizing staphylococcal wall teichoic acid induces complement-mediated opsonophagocytosis against *Staphylococcus aureus*. *J Immunol*. 2012; 189:4951–4959. [PubMed: 23071283]
34. Park KH, Kurokawa K, Zheng L, Jung DJ, Tateishi K, Jin JO, Ha NC, Kang HJ, Matsushita M, Kwak JY, Takahashi K, Lee BL. Human serum mannose-binding lectin senses wall teichoic acid Glycopolymer of *Staphylococcus aureus*, which is restricted in infancy. *J Biol Chem*. 2010; 285:27167–27175. [PubMed: 20592033]
35. Takahashi K, Kurokawa K, Moyo P, Jung DJ, An JH, Chigweshe L, Paul E, Lee BL. Intradermal immunization with wall teichoic acid (WTA) elicits and augments an anti-WTA IgG response that protects mice from methicillin-resistant *Staphylococcus aureus* infection independent of mannose-binding lectin status. *PLoS One*. 2013; 8:e69739. [PubMed: 23936347]
36. Fura JM, Sabulski MJ, Pires MM. D-amino acid mediated recruitment of endogenous antibodies to bacterial surfaces. *ACS Chem Biol*. 2014; 9:1480–1489. [PubMed: 24870969]
37. An JH, Kurokawa K, Jung DJ, Kim MJ, Kim CH, Fujimoto Y, Fukase K, Coggeshall KM, Lee BL. Human SAP is a novel peptidoglycan recognition protein that induces complement-independent phagocytosis of *Staphylococcus aureus*. *J Immunol*. 2013; 191:3319–3327. [PubMed: 23966633]
38. Atilano ML, Yates J, Glittenberg M, Filipe SR, Ligoxygakis P. Wall teichoic acids of *Staphylococcus aureus* limit recognition by the drosophila peptidoglycan recognition protein SA to promote pathogenicity. *PLoS Pathog*. 2011; 7:e1002421. [PubMed: 22144903]
39. Atilano ML, Pereira PM, Vaz F, Catalao MJ, Reed P, Grilo IR, Sobral RG, Ligoxygakis P, Pinho MG, Filipe SR. Bacterial autolysins trim cell surface peptidoglycan to prevent detection by the *Drosophila* innate immune system. *eLife*. 2014; 3:e02277. [PubMed: 24692449]
40. Kuru E, Hughes HV, Brown PJ, Hall E, Tekkam S, Cava F, de Pedro MA, Brun YV, Van Nieuwenhze MS. In Situ probing of newly synthesized peptidoglycan in live bacteria with fluorescent D-amino acids. *Angew Chem, Int Ed*. 2012; 51:12519–12523.
41. Gautam S, Kim T, Shoda T, Sen S, Deep D, Luthra R, Ferreira MT, Pinho MG, Spiegel DA. An activity based probe for studying crosslinking in live bacteria. *Angew Chem, Int Ed*. 2015; 54:10492.


**Figure 1.**

Antibodies are recruited to chemical epitopes within the *S. aureus* cell wall when WTAs are absent. (a) *spa S. aureus* Newman was labeled with K(FITC)-LPETG, K(FITC)-EGTLP, or DMSO vehicle control with or without  $0.1 \mu\text{g mL}^{-1}$  tunicamycin and then incubated with  $5 \mu\text{g mL}^{-1}$  DyLight 649-conjugated anti-FITC antibody. Antibody recruitment was assessed by measuring total cell FL-4 fluorescence (from the DyLight 649 fluorophore) via flow cytometry. (b) *tagO S. aureus* Newman was labeled with peptides and analyzed for antibody recruitment by flow cytometry as in a. (c) *spa S. aureus* Newman was labeled with K(FITC)-LPETG with or without  $0.1 \mu\text{g mL}^{-1}$  tunicamycin, and then incubated with anti-FITC antibodies. Fluorophore quenching was assessed by measuring total cell FL-1 fluorescence (from FITC) on a flow cytometer and expressed as a percentage of the fluorescence of unopsonized bacteria. Equimolar anti-DNP antibodies were used as a control. (d) *spa S. aureus* Newman was labeled with K(FITC)-LPETG, K(FITC)-EGTLP, or DMSO vehicle control with or without  $0.1 \mu\text{g mL}^{-1}$  tunicamycin, and then incubated with DyLight 649-conjugated anti-FITC antibody. Widefield imaging was performed to visualize antibody localization. The magnified inset represents an image after deconvolution processing. Flow cytometry data shown are representative of multiple independent trials performed in technical duplicate; error bars indicate SEM. \* denotes a P value  $<0.05$ . \*\*\* denotes a P value  $<0.001$ . Scale bar:  $5 \mu\text{m}$ . Abbreviations: TCM, tunicamycin; WTA, wall teichoic acids.




**Figure 2.**

Antibodies bind predominantly to superficial PG-bound epitopes. *spa S. aureus* Newman was labeled with K(A488)-LPETG with or without  $0.1 \mu\text{g mL}^{-1}$  tunicamycin and then incubated with anti-Alexa 488 primary antibodies, followed by Alexa 568-conjugated secondary antibodies. (a) Widefield imaging analysis was performed to visualize epitope and antibody localization. The magnified inset represents a dividing cell with peripherally located antibodies. (b) Structured illumination microscopy (SIM) imaging analysis was performed to visualize epitope and antibody localization at super resolution. Scale bar in (a):  $5 \mu\text{m}$ . Scale bar in (b):  $1 \mu\text{m}$ .



**Figure 3.**

Streptavidin recruitment to PG-bound biotin requires WTA depletion. WT *S. aureus* Newman was labeled with K(biotin)-LPETG, K(biotin)-EGTLP, or DMSO control with or without  $0.1 \mu\text{g mL}^{-1}$  tunicamycin and then incubated with Alexa 647-conjugated streptavidin. Protein recruitment was assessed by measuring total cell FL-4 fluorescence (from Alexa 647) on a flow cytometer. Experiment performed in technical duplicate; error bars indicate SEM. \*\* denotes a P value  $<0.01$ . Abbreviations: TCM, tunicamycin; WTA, wall teichoic acids.



**Figure 4.** Schematic of wall teichoic acids shielding cell wall epitopes from opsonins in *S. aureus*. K(FITC)-LPETG incorporated into the cell wall of *S. aureus* by sortase A is inaccessible to antibodies unless WTAs are depleted by tunicamycin treatment or by deletion of genes in the WTA biosynthetic pathway.